Innovations in Molecular Biomarkers and Biomaterial-Based Immunotherapies for Head & amp; Neck Cancer

AbstractPurpose of ReviewOral squamous cell carcinoma (OSCC) survival rates have remained stagnant due to a lack of targeted therapies and diagnostic tools. Patient risk is currently determined solely through clinicopathologic features, primarily tumor staging, which lacks the necessary precision to stratify patients by risk and accurately dictate adjuvant treatment. Similarly, conventional OSCC therapies have well-established toxicities and limited efficacy.Recent FindingsRecent studies show that patient risk can now be assessed using non-invasive techniques, at earlier time points, and with greater accuracy using molecular biomarker panels. Additionally, novel immunotherapies not only utilize the host ’s immune response to combat disease but also have the potential to form immunological memory to prevent future recurrence. Localized controlled-release formulas have further served to reduce toxicity and allow the de-escalation of other treatment modalities.SummaryWe review the latest advances in head and neck cancer diagnosis and treatment, including novel molecular biomarkers and immunotherapies.
Source: Current Surgery Reports - Category: Surgery Source Type: research